Article Versions Notes

Alamón C, Dávila B, García MF, Sánchez C, Kovacs M, Trias E, Barbeito L, Gabay M, Zeineh N, Gavish M, et al. Sunitinib-Containing Carborane Pharmacophore with the Ability to Inhibit Tyrosine Kinases Receptors FLT3, KIT and PDGFR-β, Exhibits Powerful In Vivo Anti-Glioblastoma Activity. Cancers. 2020; 12(11):3423. https://doi.org/10.3390/cancers12113423

Alamón, Catalina, Belén Dávila, María Fernanda García, Carina Sánchez, Mariángeles Kovacs, Emiliano Trias, Luis Barbeito, Martín Gabay, Nidal Zeineh, Moshe Gavish, and et al. 2020. "Sunitinib-Containing Carborane Pharmacophore with the Ability to Inhibit Tyrosine Kinases Receptors FLT3, KIT and PDGFR-β, Exhibits Powerful In Vivo Anti-Glioblastoma Activity" Cancers 12, no. 11: 3423. https://doi.org/10.3390/cancers12113423

Alamón, C., Dávila, B., García, M. F., Sánchez, C., Kovacs, M., Trias, E., Barbeito, L., Gabay, M., Zeineh, N., Gavish, M., Teixidor, F., Viñas, C., Couto, M., & Cerecetto, H. (2020). Sunitinib-Containing Carborane Pharmacophore with the Ability to Inhibit Tyrosine Kinases Receptors FLT3, KIT and PDGFR-β, Exhibits Powerful In Vivo Anti-Glioblastoma Activity. Cancers, 12(11), 3423. https://doi.org/10.3390/cancers12113423